omeprazole has been researched along with celecoxib in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (55.26) | 29.6817 |
| 2010's | 17 (44.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alarcón de la Lastra, C; Berenguer, B; Martín, MJ; Moreno, FJ | 1 |
| Daspet, MK; Gscheidel, D; Le Coz, CJ; Lipsker, D | 1 |
| Chan, FK; Chung, SC; Hui, AJ; Hung, LC; Lee, KC; Leung, VK; Leung, WK; Suen, BY; Sung, JJ; To, KF; Wong, VW; Wu, JC | 1 |
| Graham, DY | 1 |
| Dahl, ML; Eliasson, E; Griskevicius, L; Hassan, M; Hidestrand, M; Sandberg, M; Tybring, G; Yasar, U | 1 |
| Lanas, A | 1 |
| Lems, WF; Nurmohamed, MT | 1 |
| Chan, FK; Ho, JT; Lau, WH; Lee, KK; Lee, VW; Suen, BY; Sung, JY; You, JH; Yung, MY | 1 |
| Oviedo, JA; Wolfe, MM | 1 |
| Chan, FK; Chung, SC; Hui, AJ; Hung, LC; Lee, YT; Leung, WK; Suen, BY; Sung, JJ; To, KF; Wong, VW; Wu, JC | 1 |
| Cryer, B | 1 |
| Eisen, GM; Fort, JG; Goldstein, JL; Gralnek, IM; Lewis, B; Zlotnick, S | 1 |
| Chiou, CF; Ofman, JJ; Spiegel, BM | 1 |
| Gautam, P; Poonam, D; Vinay, CS | 1 |
| Scheiman, JM | 1 |
| Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM | 1 |
| Aisenberg, J; Berger, MF; Bhadra, P; Eisen, GM; Goldstein, JL; Gralnek, IM; Lewis, B | 1 |
| Berger, M; Chan, FK; Niculescu, L; Peura, D; Wilcox, CM | 1 |
| Andersson, M; Arvidsson, A; Brevinge, H; Lagerstedt, K; Lönnroth, C; Lundholm, K; Nordgren, S | 1 |
| Bernatsky, S; Rahme, E | 1 |
| Berger, MF; Chan, FK; Goldstein, JL; Lanas, A; Nguyen, H; Scheiman, J | 1 |
| Jobe, BA; Lombard, CM; Triadafilopoulos, G | 1 |
| Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL | 1 |
| Feng, GS; Lam, S; Li, J; Li, JY; Liu, WD; Lu, AP; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD | 1 |
| Blackler, R; Bolla, M; Ongini, E; Syer, S; Wallace, JL | 1 |
| Chan, FK; Goldstein, JL; Lanas, A; Li, C; Peura, DA; Sands, GH; Scheiman, JM; Wilcox, CM | 1 |
| Essex, MN; Kellner, HL; Li, C | 1 |
| Fukazawa, H; Inoue, M; Kaneko, Y; Miyazaki, Y; Niki, M; Ohno, H; Tanabe, K; Umeyama, T; Urai, M | 1 |
| Buttgereit, F; Spies, CM; Stemmler, E | 1 |
| Li, JY; Ma, JL; Pan, KF; Shen, L; You, WC; Zhang, L; Zhang, Y; Zhou, T | 1 |
3 review(s) available for omeprazole and celecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Enzyme Inhibitors; Gastrointestinal Hemorrhage; Humans; Lactones; Misoprostol; Omeprazole; Osteoarthritis; Proton Pump Inhibitors; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones | 2003 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Lactones; Lansoprazole; Naproxen; Omeprazole; Proton Pump Inhibitors; Pyrazoles; Rheumatology; Sulfonamides; Sulfones | 2005 |
13 trial(s) available for omeprazole and celecoxib
| Article | Year |
|---|---|
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter pylori; Humans; Isoenzymes; Membrane Proteins; Omeprazole; Peptic Ulcer Hemorrhage; Probability; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Secondary Prevention; Stomach Ulcer; Sulfonamides | 2002 |
Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Male; Omeprazole; Peptic Ulcer Hemorrhage; Pyrazoles; Risk Factors; Sulfonamides | 2003 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Pyrazoles; Recurrence; Sulfonamides | 2004 |
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.
Topics: Adolescent; Adult; Aged; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Humans; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Naproxen; Omeprazole; Probability; Prospective Studies; Pyrazoles; Reference Values; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Sulfonamides; Video Recording | 2005 |
What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel?
Topics: Adult; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Naproxen; Omeprazole; Prospective Studies; Pyrazoles; Sulfonamides | 2005 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Middle Aged; Naproxen; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Prospective Studies; Proton Pump Inhibitors; Pyrazoles; Recurrence; Risk Factors; Sulfonamides; Treatment Outcome | 2005 |
Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Celecoxib; Drug Therapy, Combination; Female; Humans; Ibuprofen; Intestinal Diseases; Intestinal Mucosa; Male; Middle Aged; Omeprazole; Pyrazoles; Sulfonamides | 2007 |
Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Movement; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dendritic Cells; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HLA-D Antigens; Humans; Indomethacin; Lymphocyte Subsets; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Middle Aged; Neoplasm Proteins; Omeprazole; Premedication; Preoperative Care; Pyrazoles; Sulfonamides | 2008 |
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lower Gastrointestinal Tract; Male; Middle Aged; Omeprazole; Osteoarthritis; Peptic Ulcer; Pyrazoles; Research Design; Risk Assessment; Risk Factors; Sulfonamides; Treatment Outcome; Upper Gastrointestinal Tract | 2010 |
Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; Clarithromycin; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Precancerous Conditions; Pyrazoles; Stomach; Stomach Neoplasms; Sulfonamides | 2012 |
Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR).
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Female; Hematocrit; Hemoglobins; Humans; Male; Middle Aged; Omeprazole; Osteoarthritis; Proton Pump Inhibitors; Pyrazoles; Risk Factors; Sulfonamides | 2012 |
Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Humans; Omeprazole; Prospective Studies; Pyrazoles; Sulfonamides | 2012 |
Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; China; Clarithromycin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Precancerous Conditions; Stomach; Stomach Neoplasms | 2015 |
22 other study(ies) available for omeprazole and celecoxib
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dipyrone; Enzyme Inhibitors; Female; Gastric Mucosa; Isoenzymes; Male; Membrane Proteins; Omeprazole; Piroxicam; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Rats; Rats, Wistar; Stomach; Stomach Ulcer; Sulfonamides; Time Factors; Wound Healing | 2002 |
[Allergic vasculitis following ingestion of celecoxib?].
Topics: Administration, Oral; Aged; Celecoxib; Cyclooxygenase Inhibitors; Diagnosis, Differential; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Omeprazole; Proton Pump Inhibitors; Pyrazoles; Sulfonamides; Vasculitis, Leukocytoclastic, Cutaneous | 2002 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Isoenzymes; Membrane Proteins; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2002 |
Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.
Topics: Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases; Celecoxib; Cyclophosphamide; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Genotype; Humans; Hydroxylation; In Vitro Techniques; Microsomes; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Pyrazoles; Saccharomyces cerevisiae; Sulfonamides | 2003 |
Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Isoenzymes; Membrane Proteins; Omeprazole; Peptic Ulcer Hemorrhage; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Risk Factors; Secondary Prevention; Sulfonamides | 2003 |
Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Contraindications; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Humans; Kidney Diseases; Omeprazole; Peptic Ulcer Hemorrhage; Pyrazoles; Risk Factors; Secondary Prevention; Sulfonamides | 2003 |
[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endoscopy, Digestive System; Gastric Mucosa; Humans; Intestinal Mucosa; Isoenzymes; Membrane Proteins; Middle Aged; Naproxen; Omeprazole; Osteoarthritis; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides | 2004 |
COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Humans; Isoenzymes; Membrane Proteins; Omeprazole; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Sulfonamides | 2004 |
Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing.
Topics: Animals; Anti-Ulcer Agents; Blotting, Western; Celecoxib; Chronic Disease; Cyclooxygenase 2; Dinoprostone; Female; Gastric Mucosa; Male; Misoprostol; Omeprazole; Peroxidase; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Sulfonamides; Wound Healing | 2005 |
Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Diclofenac; Humans; Omeprazole; Peptic Ulcer; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides | 2008 |
NSAIDs and risk of lower gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Colonic Diseases; Diclofenac; Gastrointestinal Hemorrhage; Humans; Lower Gastrointestinal Tract; Omeprazole; Osteoarthritis; Peptic Ulcer Hemorrhage; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sulfonamides; Upper Gastrointestinal Tract | 2010 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celecoxib; Drug Therapy, Combination; Endoscopy; Esophageal Neoplasms; Fundoplication; Gastroesophageal Reflux; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Omeprazole; Pyrazoles; Quality of Life; Sulfonamides; Treatment Outcome | 2011 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bifidobacterium; Celecoxib; Colon; Denaturing Gradient Gel Electrophoresis; Disease Models, Animal; Drug Interactions; Gastrointestinal Hemorrhage; Hematocrit; Jejunum; Lansoprazole; Male; Naproxen; Omeprazole; Peptic Ulcer; Probiotics; Proton Pump Inhibitors; Pyrazoles; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Time Factors | 2011 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combination; Gastric Mucosa; Gastrointestinal Diseases; Gastrointestinal Tract; Hypertension; Male; Naproxen; Nitrates; Obesity; Omeprazole; Pyrazoles; Rats; Rats, Inbred SHR; Rats, Wistar; Rats, Zucker; Sulfonamides | 2012 |
Potent drugs that attenuate anti-Candida albicans activity of fluconazole and their possible mechanisms of action.
Topics: Antifungal Agents; ATP-Binding Cassette Transporters; Candida albicans; Candidiasis; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Fluconazole; Fungal Proteins; Gene Expression; Ibuprofen; Membrane Transport Proteins; Microbial Sensitivity Tests; Omeprazole; Phenylpropionates; Proton Pump Inhibitors | 2014 |
How to mechanistically explain the CONDOR study data.
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Intestinal Mucosa; Models, Molecular; Molecular Structure; Omeprazole; Osteoarthritis; Oxidative Phosphorylation; Proton Pump Inhibitors; Pyrazoles; Sulfonamides | 2015 |